CommercialCoverageMedium impact
11.08.17k, Debridement of Mycotic and Symptomatic Non-Mycotic Hypertrophic Toenails
Independence Blue Cross·Podiatry, Dermatology·Medical Policy
Effective date
Apr 2, 2025
We identified it
Jun 19, 2026
Summary
IBX Commercial has reissued policy 11.08.17k regarding debridement of mycotic and symptomatic non-mycotic hypertrophic toenails. This is a policy reissue that will become effective April 2, 2025, suggesting updates to coverage or billing requirements for toenail debridement procedures.
Action Required
By April 2, 2025: Billing team must review the complete policy document at the provided URL to identify specific changes to toenail debridement billing requirements. Update billing procedures, prior authorization requirements, and documentation standards as specified in the full policy. Notify podiatry and dermatology providers of any new requirements.